European Medicines Agency official links AstraZeneca vaccine and thrombosis
A top official in the European Medicines Agency said in an interview published Tuesday that there was an established link between the AstraZeneca coronavirus vaccine and blood clots. The EMA however denied it had found a link but would publish its conclusions later in the week.
"In my opinion, we can say it now, it is clear there is a link with the- vaccine. But we still do not know what causes this reaction," EMA head of vaccines Marco Cavaleri told Italy's Il Messaggero newspaper.
He said that "in the next few hours, we will say that there is a connection, but we still have to understand how this happens".
However later on Tuesday the EMA released a statement to AFP saying it had "not yet reached a conclusion and the review is currently ongoing" adding that it expected to announce its findings later in the week.
Persistent questions on whether rare but serious blood clots among those getting the AstraZeneca jab against Covid-19 are more frequent than in the general population have undermined confidence in the beleaguered vaccine.
After several countries suspended the use of the jab -- including Italy -- the EMA declared that the benefits outweigh the risks and it should remain in use.
READ ALSO: In Europe doubts linger over possible AstraZeneca jab side effects
But it has said that a causal link between clots and the vaccine is possible, and is expected to provide an updated assessment this week.
"We are trying to get a precise picture of what is happening, to define in detail this syndrome due to the vaccine," Cavaleri said.
He added: "Among the vaccinated, there are more cases of cerebral thrombosis... among young people than we would expect."
The EMA has consistently said that “The benefits of the AstraZeneca vaccine in preventing Covid-19, with its associated risk of hospitalisation and death, outweigh the risks of side effects."
But in its statement on March 31st the agency added: "A causal link with the vaccine is not proven, but is possible and further analysis is continuing."
As of March 31st, the EMA had identified 62 cases of cerebral venous sinus thrombosis (CVST) in the world – 44 of them in Europe – among 9.2 million doses of AstraZeneca administered.
Of those, 14 have resulted in death, though it is not possible to definitively attribute fatalities to this rare form of thrombosis, the head of the EMA, Emer Cook, said last week in a videoconference.
In Germany, there have been 31 suspected cases of CVST – 19 accompanied by a drop in blood platelets – with nine deaths, according to the Paul-Ehrlich Institute.
These cases were spread across 2.8 million AstraZeneca vaccine doses injected, or just over one case per 100,000 doses.
The comparable figures for France are 12 cases and four deaths out of 1.9 million doses, and for Norway, five cases and three deaths out of 120,000 doses.
Britain – where AstraZeneca has been administered more than in any other country – registered 30 cases as of Saturday, including seven fatalities, across a total of 18.1 million doses.
But as is true of all medications, risks must always be weighed against benefits.
Comments (1)
See Also
"In my opinion, we can say it now, it is clear there is a link with the- vaccine. But we still do not know what causes this reaction," EMA head of vaccines Marco Cavaleri told Italy's Il Messaggero newspaper.
He said that "in the next few hours, we will say that there is a connection, but we still have to understand how this happens".
However later on Tuesday the EMA released a statement to AFP saying it had "not yet reached a conclusion and the review is currently ongoing" adding that it expected to announce its findings later in the week.
Persistent questions on whether rare but serious blood clots among those getting the AstraZeneca jab against Covid-19 are more frequent than in the general population have undermined confidence in the beleaguered vaccine.
After several countries suspended the use of the jab -- including Italy -- the EMA declared that the benefits outweigh the risks and it should remain in use.
READ ALSO: In Europe doubts linger over possible AstraZeneca jab side effects
But it has said that a causal link between clots and the vaccine is possible, and is expected to provide an updated assessment this week.
"We are trying to get a precise picture of what is happening, to define in detail this syndrome due to the vaccine," Cavaleri said.
He added: "Among the vaccinated, there are more cases of cerebral thrombosis... among young people than we would expect."
The EMA has consistently said that “The benefits of the AstraZeneca vaccine in preventing Covid-19, with its associated risk of hospitalisation and death, outweigh the risks of side effects."
But in its statement on March 31st the agency added: "A causal link with the vaccine is not proven, but is possible and further analysis is continuing."
As of March 31st, the EMA had identified 62 cases of cerebral venous sinus thrombosis (CVST) in the world – 44 of them in Europe – among 9.2 million doses of AstraZeneca administered.
Of those, 14 have resulted in death, though it is not possible to definitively attribute fatalities to this rare form of thrombosis, the head of the EMA, Emer Cook, said last week in a videoconference.
In Germany, there have been 31 suspected cases of CVST – 19 accompanied by a drop in blood platelets – with nine deaths, according to the Paul-Ehrlich Institute.
These cases were spread across 2.8 million AstraZeneca vaccine doses injected, or just over one case per 100,000 doses.
The comparable figures for France are 12 cases and four deaths out of 1.9 million doses, and for Norway, five cases and three deaths out of 120,000 doses.
Britain – where AstraZeneca has been administered more than in any other country – registered 30 cases as of Saturday, including seven fatalities, across a total of 18.1 million doses.
But as is true of all medications, risks must always be weighed against benefits.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.